Annette S. Kim is an Associate Professor of Pathology at Harvard Medical School and a practicing hematopathologist and molecular pathologist at Brigham and Women's Hospital. She has prior training in synthetic organic chemistry as well as structural biology and spent several years in the pharmaceutical industry prior to her return to academia. In the pharmaceutical industry, she both conducted drug discovery medicinal chemistry and led a target validation program within Cancer Biology. Since returning to clinical practice in hematopathology and molecular pathology, her research program has focused on the study of normal and aberrant hematopoiesis, particularly in the study of hematolymphoid malignancies. She has identified diagnostic and prognostic small non-coding RNAs in MDS via next generation sequencing and has defined the role of hypermethylation in the regulation of miRNAs in MDS. She studies the effects of potential therapeutic compounds on cellular function in miRNA-based models of the MDS and in primary clinical samples using single cell phenotyping by mass cytometry with correlation to the mutational profiles of these samples. In addition, she receives funding for her efforts in test utilization management, conducting studies on cost effective practice of hematopathology.